P1/2, N=63, Terminated, Nerviano Medical Sciences | N=200 --> 63 | Trial completion date: Feb 2026 --> Aug 2024 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Aug 2024; Study stopped due to strategic reasons. The decision is not based on specific safety findings as the safety observed in the phase II part of the study is in line with what was reported in the phase I part.

3 months ago

Enrollment change • Trial completion date • Trial termination • Trial primary completion date

FLT3 (Fms-related tyrosine kinase 3)

FLT3-ITD mutation

NMS-088

10ms

Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML (clinicaltrials.gov)

P1/2, N=200, Recruiting, Nerviano Medical Sciences | N=140 --> 200 | Trial completion date: Sep 2023 --> Feb 2026 | Trial primary completion date: Sep 2023 --> Dec 2025

10 months ago

Enrollment change • Trial completion date • Trial primary completion date

FLT3 (Fms-related tyrosine kinase 3)

FLT3-ITD mutation

NMS-088

over3years

Study of first administration in humans and efficacy of NMS-03592088, an inhibitor of FLT3, KIT and CSF1R, in patients with Relapsing or Drug-resistant Acute Myeloid Leukemia (LMA) and Chronic Myelomonocytic Leukemia (LMMC). Studio di prima somministrazione nell'uomo e di efficacia di NMS-03592088, un inibitore di FLT3, KIT e CSF1R, in pazienti con Leucemia Mieloide Acuta (LMA) e Leucemia Mielomonocitica Cronica (LMMC) recidivanti o resistenti a farmaci. (clinicaltrialsregister.eu)

P1/2, N=165, Ongoing, NERVIANO MEDICAL SCIENCES SRL

over 3 years ago

Clinical • New P1/2 trial

FLT3 (Fms-related tyrosine kinase 3)

FLT3-ITD mutation • FLT3 mutation

NMS-088